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Background: Low-dose spiral computed tomography (sCT) showed a four-fold increase in the
detection rate in high-risk subjects and a higher percentage of stage I lung cancer in comparison with
chest X-ray. However, there is a considerable discrepancy among studies in the percentage of lung
nodules, overall lung cancer and stage I detection rate.
Subjects and methods: From April to December 2001, 520 asymptomatic volunteers aged ‡55 years
with a history of cigarette smoking ‡20 pack-years and no previous cancer were enrolled to receive an
annual sCT of the chest for five consecutive years.
Results: Seventy three per cent were male, median age was 59 years and 91% were current smokers.
At baseline, nodules ‡5 mm were detected in 114 (22%) undergoing sCT; the size of lung nodules
ranged from 5 to 9.9 mm in 81.5% of the cases. Five (1%) cases of lung cancer were detected. In two
additional cases a pathological diagnosis of atypical adenomatous hyperplasia was made. Three new
cases of lung cancer were detected in the second and third year of the study. One interval case was
detected during the third year.
Conclusions: Despite some promising data, convincing evidence from ongoing randomized trials is
needed to support the routine use of sCT as a recommended tool for screening of lung cancer.
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Introduction
Current smokers are clearly at increased risk for lung cancer, but
even former smokers continue to be at increased risk for many
years after quitting [1]. Smoking cessation and early detection
are critical goals for lung cancer prevention and control.
In lung cancer, the cure rate is highly stage-dependent, being
significantly higher in stage I, but unfortunately the proportion
of patients clinically diagnosed in this stage is very limited [2]
and to date no screening tool has been recognized to be defini-
tively effective in significantly reducing lung cancer mortality.
The negative view about lung cancer screening came from dis-
appointing results of large randomized, controlled trials con-
ducted in the 1970s that failed to show any mortality reduction
when chest X-rays or sputum cytology were used as potential
screening tools in high-risk populations [3–6].
Low-dose spiral computed tomography (sCT) can detect lung
nodules of only 2 mm and it is four times more sensitive than
standard chest X-ray, but, especially in the central lung areas,
nodular lesion can be missed by the radiologist because of mis-
interpretation of cross-sectioned small blood vessel imaging. When
compared with the standard CT technique, low-dose sCT is less
costly, faster and entails lower radiation exposure (0.5 versus
5.0 mSv) [7].
Interest in lung cancer screening was primarily revamped by
the ELCAP study results, in which baseline screening detected
27 cases of malignant lung disease, of which 23 (85%) were
found at stage I and 26 underwent curative surgical resection [8].
Subsequently, several non-randomized studies concluded that
the resection of CT screening-detected early-stage lung cancer
results in a higher cure rate (for review see Bepler et al. [9]).
This feasibility study was performed to verify the applicabil-
ity of low-dose sCT as a diagnostic tool for early lung cancer
detection in the setting of a university hospital (University of
Turin, San Luigi Hospital) and it was planned and initiated at
approximately the same time as a similar study was being
performed at the European Institute of Oncology in Milan [10].
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The primary end points of this study were to determine the
prevalence of malignant pulmonary disease at the baseline sCT
examination and to assess the radiological detection of disease
during the 5-year follow-up. Secondary objectives included the
determination of the overall resectability of detected malignant
tumors, the assessment of the proportion of cases resected for
pathological stage pIA (survival 70–80%) and the evaluation
of the costs by estimated years of life saved.
This preliminary report is focused on the prevalence of lung
cancer at the baseline examination as well as in the subsequent
2 years, the assessment of overall resectability, and the morbid-
ity and mortality associated with surgical resection.
Subjects and methods
Up to 500 subjects considered to be at high risk for lung cancer were asked
to volunteer for annual low-dose sCT examination for five consecutive
years. The study population was defined by inclusion criteria as follows:
age ‡55 years, current daily smokers or former smokers (up to 10 years
before), ‡20 pack-years (calculated by multiplying the number of packs
per day by the total number of years smoked) and with no personal history
of malignancy.
Those subjects who were willing to participate were assessed for their
eligibility to enter in the early detection study by means of a phone ques-
tionnaire.
The study was conducted under the approval of the ethical review board
of the Piedmont region, and followed the guidelines for good clinical pract-
ice. The recommendations of the Declaration of Helsinki for biomedical re-
search involving human subjects were also followed. The study did not
receive any private or public funding and the personnel volunteered to take
part in the project.
Each subject first signed an informed consent form for his/her participa-
tion in the study and if he/she agreed, on the same day blood, urine and
sputum samples were collected.
Baseline and annual low-dose sCT scans of the thorax (without contrast)
were performed on a double slice sCT scanner (Elscint Twin; Elscint, Haifa,
Israel) at 120 kV peak, 33 mA and pitch 1.5, with a collimation of 8.8 mm
and 5 mm reconstruction interval. The images, encompassing the entire lung
region, were acquired in a single breath-hold at end-inspiration after hyper-
ventilation and were reconstructed with overlapping at 4 mm intervals. All
investigations were sent to a workstation and immediately archived on
CD-rom in dicom format (one CD for each session). In this study, chest
radiographs and lung function tests were not prospectively studied.
Two board-certified chest radiologists independently evaluated the scans
for inter-observer variability. In the case of disagreement, a senior radiolo-
gist acted as arbiter to reach an agreement.
Every subject was to be followed up for 5 years with annual scans, and
monitored for smoking habit.
Diagnostic algorithm
Baseline examinations without non-calcified pulmonary nodules were
regarded as negative and subjects were invited to undergo repeated low-dose
sCT one year later. Homogeneously calcified nodules were considered as
benign and subjects were invited to repeat low-dose sCT one year later, as
were non-calcified nodule(s) with a maximum trasverse diameter <5 mm.
If solitary or multiple nodules ‡5 mm were detected, further diagnostic
procedures were determined by size of the nodule(s) and attenuation
coefficient. The protocol called for inclusive reading, so that ground-glass
opacities were counted as nodules.
Nodule attenuation was recorded as non-calcified or as partially or homo-
geneously calcified by using an arbitrary threshold of 200 Hounsfield units
(HU) to differentiate between calcification and soft-tissue attenuation.
Within 1 month all subjects with one or more nodule(s) with a diameter
‡5 mm were referred to a contrast medium chest CT scan with enhancement
assessment. All the images were viewed at both lung and mediastinal win-
dows. Based on a previous experience on the likelihood of malignancy at
sCT [11] and, at the same time, to limit the possibility of false-positive rate,
the contrast enhancement was considered as follows: <20 HU, negative;
20 HU, suspicious; and >20 HU, positive. If the probability of malignancy
was considered low (size <10 mm and enhancement <20 HU), follow-up
with repeat at 3, 6 and 12 months after baseline examination was considered
case by case, using 1-mm collimation with overlapping 0.5-mm reconstruc-
tions. For nodules >11 mm and with an HU value ‡20, surgical intervention
was always considered. From the second year only, standard-dose CT with
thin sections (1–3 mm) was used to further analyze and follow-up new
nodules or any increase in size of any previously detected nodule.
At the subsequent annual sCT, the absence of growth of the nodule(s) in
the 12-month period was considered as evidence of a benign lesion. Growth
was defined as an increase of the nodule’s diameter in at least one dimension.
In our study PET scan was not routinely performed; however, subjects
with positive enhancement were occasionally considered for this diagnostic
procedure.
Radically resected subjects were assessed for post-surgical morbidity and
mortality and followed up according to standard criteria (every 3 months for
the first 2 years and then twice yearly). Resected specimens were classified
according to WHO classification for lung tumors [12].
Results
Enrolment in the feasibility project was limited to a cohort of
520 high-risk individuals; one subject was found ineligible at
the time of baseline questionnaire. The median age was 59
years (range 54–79), 91% were current smokers and 26.5%
were females (Table 1).
Baseline low-dose CT identified 114 subjects as having one
to six non-calcified nodule(s) with a largest diameter ‡5 mm,
and 127 subjects having one to six non-calcified nodule(s)
with a largest diameter <5 mm. The nodule size was distributed
as follows: 5–9.9 mm, 98; 10–19.9 mm, 11; >20 mm, five.
Among 278 subjects with a nodule(s), the distribution in number
Table 1. Demographic data (n = 520)
Characteristics Number of
subjects
%
Male 382 73.5
Female 138 26.5
Age at screening (median 59 years)
55–59 years 278 53.4
60–64 years 168 32.3
65–69 years 51 9.8
70–74 years 19 3.6
>75 years 4 0.7
Smoking status
Former 46 8.9
Current 474 91.1
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was as follows: one nodule, 116; two to six nodules, 118; more
than six nodules, seven (Table 2).
Within 1 month, 114 subjects with a nodule(s) >5 mm
received a contrast-enhanced (n = 49) or standard-dose (n = 65)
CT scan. In 28 cases the nodular lesions were judged as false
positive owing to blood vessel crossing, inflammatory lesions
or the stigma of a previous tuberculosis. The reason for the
deviation from the planned diagnostic algorithm was related
to the disappointing results after performing a contrast CT scan
in the first 49 subjects with nodules >5 mm, in which contrast-
enhancement was sufficiently reliable only in 24 out of 49
subjects.
Within the first year, 71 subjects were submitted to at least
one additional standard-dose CT scan of the nodule without
contrast enhancement.
Owing to restriction facilities, PET scan was not systemati-
cally performed in subjects with positive contrast media
enhancement; it was performed occasionally in six cases, and
in five it was completely negative. One patient with negative
PET scan was subsequently resected and a pathological diagno-
sis of bronchiolo-alveolar carcinoma was made.
Among 114 subjects as having one to six non-calcified
nodule(s) with a largest diameter ‡5 mm, five (4.3%) had a
nodule-associated malignancy: the size was 9 mm in one case,
10–15 mm in two and >20 mm in two lesions. Prevalence of
lung cancer in the study population was 1%.
Histologically, one lung cancer was an adenocarcinoma, one
a squamous cell carcinoma and three were bronchiolo-alveolar
carcinomas. The adenocarcinoma occurred in a 79-year-old
subject; it was stage IV disease (for adrenal metastases) and
the subject subsequently received single-agent chemotherapy.
The four lung cancers were completely resected and patho-
logical staging was pIA in two cases, pIB in one case and pIIIB
in another case who, after surgical resection, received adjuvant
chemo-radiotherapy.
In two additional nodules (size 6 and 20 mm), contrast
enhancement was increased between two subsequent CT invest-
igations and, after a case discussion in a multidisciplinary tho-
racic oncology clinic, submitted to radical surgery. Both cases
(one lobectomy and one atypical resection) were defined at post-
surgical pathological examination as atypical adenomatous
hyperplasia, which the current classification of lung tumors
identifies as a pre-neoplastic lesion [13]. Two years later, the
patient who underwent atypical resection developed an adeno-
carcinoma in the same lobe with chest wall involvement.
Subjects with newly detected or increased in size non-
calcified nodules ‡5 mm were 5.2% and 3.3% at year 2 and 3,
respectively (Table 3).
During the second and the third year, three cases of lung
cancer for each year were detected (Table 4). As done at the
baseline year, all the new nodules ‡5 mm or those that had in-
creased in size had at least one standard-dose chest CT scan. At
year 2, in five subjects non-nodular abnormalities were detected
at the annual sCT and during the subsequent diagnostic work-up
an endobronchial squamous cell carcinoma was diagnosed.
At the end of the first year the drop-off rate was 5%
(25 subjects) (five cases of lung cancer, two of atypical adeno-
matous hyperplasia, five other malignancies and 13 because of
subject’s decision), 4.5% (22 subjects) at the end of the second
year (three cases of lung cancers, two cancer-unrelated deaths,
10 other malignancies and seven because of subject’s decision),
and 2.3% in the third year (three cases of lung cancers, two
cancer-unrelated deaths and six other malignancies).
Table 2. Detection rate and amount of non-calcified nodules in each
subject at the baseline spiral computed tomography
Non-calcified nodules Subjects
(n = 519) [n (%)]
Absence 278 (53.5)
Presence 241 (46.5)
1 nodule 116
2–6 nodules 118
>6 nodules 7
Table 3. Summary of the new nodules and those increased in size from the
previous year during the second and the third year of the early detection
study
Year New
nodules
Nodules
increased
in size
Nodules
>5 mm
Second 25 4 26
Third 18 7 16
Table 4. Pathological findings of clearly contrast-enhanced nodules
Histologic typing Stage Diameter
(mm)
Age of
patients
(years)
Year 1 (baseline)
Bronchiolo-alveolar carcinomaa IA 13 57
Bronchiolo-alveolar carcinomab IIIB 24 73
Bronchiolo-alveolar carcinomaa IB 12 63
Adenocarcinomac IV >20 79
Squamous cell carcinoma IA 9 62
Atypical adenomatous hyperplasiaa – 20 62
Atypical adenomatous hyperplasiaa – 6 62
Year 2
Bronchiolo-alveolar carcinomaa IB 12 61
Squamous cell carcinomaa IA 12 77
Squamous cell carcinomaa IB d 58
Year 3
Squamous cell carcinomaa IB 7 59
Bronchiolo-alveolar carcinomaa IA 11 60
Carcinosarcomac IIIB 5 68
aComplete resection.
bResected and treated with adjuvant chemo-radiotherapy.
cTreated with chemotherapy.
dCT nodular lesion was diagnosed as tuberculosis but a pure endobronchial
lesion was found during the diagnostic work up.
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One interval case was observed during the third year: 6 months
later the annual sCT gave a completely negative evaluation for
nodules and the subject received a chest X-ray for other reasons
that detected a non-calcified nodule of 20 mm in the right
lobe. The subject was subsequently resected and a pathological
diagnosis of adenocarcinoma was made.
At the time of this report all of the 11 surgically resected
patients with the exception of one (the case of IIIB disease
detected at baseline) are alive and nine are currently disease-
free. Among the 11 cases of lung cancer, the proportion of
patients with stage I is 72%. No morbidity or mortality associ-
ated with surgical resection was reported.
Other detected lesions
One hundred and thirty-seven extra-pulmonary findings (26%)
were discovered during the first year, among which 6% were
adrenal adenomas, 3.4% hepatic and renal cysts, hepatic angio-
mas, renal calculosis and cholelithiasis, and in four cases an
aortic aneurysm was detected. Incidentally, a stage I renal car-
cinoma was identified and submitted to radical nefrectomy. In
all of these findings additional imaging investigations were
requested to reach a definitive diagnosis in 62 subjects, while
in the remaining 75 the abnormalities were already known and
diagnosed.
Discussion
Currently, there is preliminary evidence from non-randomized
studies that low-dose sCT is able to increase the proportion of
prevalent cases of stage I non-small-cell lung cancer, but no data
on reduction, more or less significant, in the disease-specific
mortality rate has yet been demonstrated. This information will
hopefully come from randomized clinical studies already initi-
ated throughout the world.
To verify the feasibility of such an approach in the setting of
a university hospital with a long-standing tradition in the man-
agement of respiratory diseases, in 2000 we initiated a feasibility
study enrolling >500 high risk subjects as defined by chrono-
logical age and pack-years limits. The inadequacy of the unit of
‘pack-years’ to estimate the individual lung cancer risk is a mat-
ter of debate [14], and future initiatives to develop a more appro-
priate lung cancer risk model are encouraged but, at the time
the study was initiated, this simple selection criterion, together
with a lower age limit of 55 years, was considered a straightfor-
ward way to enrich our study population. Recently, a huge
epidemiological study suggested that the incidence of lung can-
cer is higher among subjects with moderate to severe chronic
obstructive lung disease and the use of pulmonary function tests
has been suggested as a way to further select subject population
to enrol in early detection programs [15], however this proposal
needs to be prospectively validated.
Similar to another recently published paper [10], our study
adopted a simplified study design to follow-up the non-calcified
nodules detected at baseline low-dose sCT scan. For the
additional diagnostic work-up we decided to ignore nodules
with a maximum diameter £5 mm as well as those that were
calcified, based on the extremely low likelihood of malignancy
[11]. There are some relevant differences in a comparative anal-
ysis between the Milan study and our data: at baseline exami-
nation the percentage of patients with nodules >5 mm judged to
be worth further investigation was 4.4% in the Milan study and
21.9% in our study. The latter percentage is closer to that
previously reported in the Mayo experience [16]. This huge
difference may be partially related to the interpretation of the
CT findings, which may be partially secondary to the radiolog-
ists’ training in thoracic imaging, as indirectly confirmed by the
observation in the Milan study that 54% of the newly detected
tumors in the 2-year screening were visible at the baseline
low-dose CT scan. In the perspective of huge randomized,
multicenter studies, the use of a training set of radiological
slides should be mandatory as a way of increasing the quality
control of the study, and each participating center should in-
clude at least one radiologist with a well-recognized training
in thoracic imaging. Despite these potential improvements, only
the use of a computer-aided diagnosis system, as recently sug-
gested [17, 18], will really help radiologists in the detection of
pulmonary nodules.
As previously reported in similar studies, most of the lung
cancers detected at the baseline were adenocarcinomas (four out
of five), and in only one case was the diagnosis of squamous cell
carcinoma made. Similarly, the overall findings over the 3 years
of this feasibility study consistently confirm data about the
higher incidence of adenocarcinomas and of stage I disease
(72% in the current study). In addition, two cases of ground-
glass opacity were detected that at the subsequent pathological
examination both resulted in being atypical adenomatous
hyperplasia. This lesion is currently considered by the WHO
classification as a pre-neoplastic lesion preceding the develop-
ment of an overt, solid adenocarcinomas [13], as documented in
one of our cases.
Data from repeated follow-ups indicate a progressive
decrease in the annual rate of newly diagnosed cancer, and this
finding has been fully confirmed by our data. This issue raises
another relevant question concerning the frequency of the fol-
low-up. The choice of repeating the low-dose sCT scan annually
was based on empirical observations, but no objective data are
available that strongly support this decision, and a reasonable
scientific question may be to determine the best frequency for
follow-up. The drop-out rate was in the range of 3–5%, which
indicates, at least in our cohort of subjects, a relatively good
compliance over the 3-year period.
Several studies have already tried to quantify the cost-
effectiveness of lung cancer early detection programs; unfortu-
nately, the conflicting results of such studies are highly
dependent on large numbers of assumptions, and are therefore
only as good as those assumptions [19–21].
Even if a low-dose sCT scan in randomized clinical studies
will significantly reduce the disease-specific mortality, the ap-
plicability of such an approach in general clinical practice could
pose significant challenges to the health-care community in terms
of technical and human resources.
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In conclusion, until more data, cheaper technology and less
invasive surgical procedures are available, together with con-
vincing evidence from ongoing randomized trials supporting
the routine use of sCT, a conservative attitude about accepting
this new early lung cancer diagnostic tool should be encouraged.
To date, the estimation of lung cancer mortality as it has been
evaluated from sCT early detection trials already published indi-
cates an outcome similar to prior chest radiography trials in
high-risk subjects [22].
References
1. Doll R, Peto R, Boreham J et al. Mortality in relation to smoking:
50 years’ observations on male British doctors. BMJ 2004; 328:
1507–1515.
2. Mountain CF. Revisions in the international system for staging lung
cancer. Chest 1997; 111: 1710–1717.
3. Melamed MR, Flehinger BJ, Zaman MB et al. Screening for lung
cancer: results of the Memorial Sloan-Kettering study in New York.
Chest 1984; 86: 44–53.
4. Fontana RS, Sanderson DR, Woolner LB et al. Lung cancer screening:
the Mayo program. J Occup Med 1986; 28: 746–750.
5. Tockman MS. Survival and mortality from lung cancer in a screened
population: The Johns Hopkins Study. Chest 1986; 89: 324S–325S.
6. Kubik A, Parkin DM, Khlat M et al. Lack of benefit from semi-annual
screening for cancer of the lung: follow-up report of a randomized
controlled trial on a population of high-risk males in Czechoslovakia.
Int J Cancer 1990; 45: 26–33.
7. Rusinek H, Naidich DP, McGuinness G et al. Pulmonary nodules detec-
tion: low dose versus conventional CT. Radiology 1998; 209: 243–249.
8. Henschke CI, McCauley DI, Yankelevitz DF et al. Early Lung Cancer
Action Project: overall design and findings from baseline screening.
Lancet 1999; 354: 99–105.
9. Bepler G, Carney DG, Djulbegovic B et al. A systematic review and
lessons learned from early lung cancer detection trials using low-dose
computed tomography of the chest. Cancer Control 2003; 10: 306–324.
10. Pastorino U, Bellomi M, Bandoni C et al. Early lung-cancer detection
with spiral CT and positron emission tomography in heavy smokers:
2-years results. Lancet 2003; 362: 593–597.
11. Swensen SJ, Jett JR, Hartman TE et al. Lung cancer screening with CT:
Mayo Clinic experience. Radiology 2003; 226: 756–761.
12. World Health Organization. Histological Typing of Lung Tumors.
Geneva: World Health Organization 1981.
13. World Health Organization. Pathology and genetics of tumours of
the lung, pleura, thymus and heart. IARC-WHO Classification of
Tumours, Vol. 10, 2004.
14. Hirsch FR, Franklin WA, Gazdar AF et al. Early detection of
lung cancer: clinical perspectives of recent advances in biology and
radiology. Clin Cancer Res 2001; 7: 5–22.
15. Mannino DV, Aguayo SM, Petty TL et al. Low lung function and
incident lung cancer in the United States: data from the first National
Health and Nutrition Examination survey follow up. Arch Intern Med
2003; 163: 1475.
16. Swensen SJ, Jett JJ, Sloan JA et al. Screening for lung cancer with low-
dose spiral computed tomography. Am J Respir Crit Care Med 2002;
165: 508–513.
17. Wormanns D, Fiebich M, Saidi M et al. Automatic detection of
pulmonary nodules at spiral CT: clinical application of a computer-
aided diagnosis system. Eur Radiol 2002; 12: 1052–1057.
18. Awai K, Murao K, Ozawa A et al. Pulmonary nodules at chest CT:
effect of computer-aided diagnosis on radiologists’ detection perfor-
mance. Radiology 2004; 230: 347–352.
19. Wisnivesky JP, Mushlin AI, Sicherman N et al. The cost-effectiveness
of low-dose CT screening of lung cancer. Preliminary results of
baseline screening. Chest 2003; 124: 614–621.
20. Mahadevia PJ, Fleisher LA, Frick KD et al. Lung cancer screening with
helical computed tomography in older adult smokers. JAMA 2003;
289: 313–322.
21. Grann VR, Neugut AI. Lung cancer screening at any price? JAMA
2003; 289: 357–358.
22. Patz EF, Swensen SJ, Herndon JE et al. Estimate of lung cancer
mortality from low-dose spiral computed tomography screening trials:
implications for current mass screening recommendations. J Clin Oncol
2004; 22: 2202–2206.
1666
Downloaded from https://academic.oup.com/annonc/article-abstract/16/10/1662/169276
by Universita degli Studi di Torino user
on 31 August 2018
